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Inpatient management 
of alcohol withdrawal: a 
practical approach 
ABSTRACT
Alcohol intake contributes directly or indirectly to 15 to 20% of medical problems in primary care or an inpatient setting.  It is 
estimated that approximately 500,000 episodes of withdrawal will be severe enough to require pharmacologic intervention. 
The total cost to the United States economy from alcohol abuse was estimated to be $185 billion for 1998. This review 
attempts to put forth a practical and evidence based approach towards the inpatient management of alcohol withdrawal. 
Various agents and their pharmacology are described. Strength of evidence regards to efficacy and shorter inpatient stays 
is examined. 
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Scope of the problem 
Two thirds of Americans drink alcohol 
and about ten percent of Americans 
abuse alcohol. Alcoholism is a very 
common problem and at some point 
every clinician will be confronted by it. 
Alcohol intake in its myriad forms con-
tributes to the genesis of 15% to 20% of 
medical diagnoses in some way. Apart 
from the medical aspects of alcohol 
related problems it continues to be a 
costly drain on health care expenditure. 
In 1998 estimated healthcare costs to 
the United States economy from alco-
hol withdrawal alone approached a 
staggering one hundred and eighty 
five billion dollars. (1) In addition some 
costs of alcohol abuse are difficult to 
quantify, such as domestic violence, 
child abuse, or loss of a promising 
future. About half a million episodes of 
alcohol withdrawal per year are severe 
enough to require pharmacologic man-
agement. (2) 
Pathophysiology
Alcohol is a central nervous system 
depressant. Abrupt cessation of alco-
hol intake unmasks the compensatory 
over activity of various parts of the cen-
tral nervous system, most notably the 
sympathetic autonomic outflow. Data 
suggests that sustained alcohol intake 
with sustained blood alcohol levels cor-
related with incidence of alcohol with-
drawal. Longer periods of sustained 
alcohol intake are more likely to pro-
duce withdrawal. (3) Neurotransmit-
ters are thought to play an important 
role in the manifestations of alcohol 
withdrawal. The gamma amino butyric 
acid (GABA) receptor is down regulated 
and its neuronal activity decreased in 
alcohol withdrawal, resulting in hyper 
arousal. (4) Elevated levels of norepi-
nephrine are found in the cerebrospinal 
fluid of patients in alcohol withdrawal. 
This is believed to be due to a decrease 
in the alpha-2 receptor-mediated inhi-
bition of presynaptic norepinephrine 
release. (5) Dysfunctional serotonergic 
neurotransmission has been linked to 
an increased propensity toward ethanol 
addiction. (6)
The alcohol withdrawal 
syndromes
Clinical manifestations of alcohol with-
drawal run the gamut from minor with-
drawal symptoms to overt delirium tre-
mens and withdrawal seizures. Table 1 
elucidates the various syndromes and 
their respective timelines with a brief 
description of the clinical manifesta-
tions.
Treatment of alcohol 
withdrawal
Supportive measures: these play a criti-
cal role in the inpatient management 
of patients in withdrawal. Frequent 
re-evaluation of the patient is of para-
mount importance since the various 
withdrawal syndromes may coexist with 
or be mimicked by other conditions. 
Infection, trauma, metabolic derange-
ments, drug overdose, hepatic failure, 
or gastrointestinal bleeding frequently 
complicate the clinical syndrome. When 
faced with altered sensorium without 
a definite cause it may be necessary 
to perform extensive testing, such as 
lumbar puncture and CT scan, to confi-
dently exclude other diagnostic consid-
erations, especially when patients pres-
ent with fever in addition to a withdrawal 
syndrome.
Patients should be placed in a quiet, 
protective environment. Mechanical 
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restraint with the patient in the lateral 
decubitus (or “swimmer’s”) position 
may be necessary for patients suffer-
ing from delirium tremens (DTs) for the 
protection of both the patient and his 
or her caretakers. Volume deficits can 
be calculated and replaced accord-
ingly or, if there are no contraindica-
tions, isotonic intravenous fluid can be 
infused rapidly until patients are clini-
cally euvolemic. Thiamine  100 mg IV or 
IM, should be administered prior to any 
glucose-containing solutions in order 
to decrease the risk of precipitating 
Wernicke’s encephalopathy (WE) or 
Korsakoff’s syndrome (KS). Multivita-
mins containing or supplemented with 
folate should be given routinely, and 
deficiencies of potassium, magnesium, 
glucose, and phosphate should be cor-
rected as needed.
Intensive Care Unit referral: most inten-
sive care patients tend to have severe 
alcohol withdrawal with electrolyte 
abnormalities that are life threatening, 
hence, indications for ICU referral is 
usually governed by clinical manifes-
Table 1. Various alcohol withdrawal syndromes.
Syndrome Clinical manifestation Onset after last drink
Minor withdrawal symptoms:
These usually resolve within 24 to 48 
hours
Tremulousness, anxiety, headache, 
diaphoresis, palpitations, GI 
symptoms including diarrhea and 
anorexia
6 to 36 hours
Alcohol related seizures,
Occur in approximately 3 % of 
chronic alcoholics
Generalized, tonic-clonic, rarely 
status epilepticus (3% of those with 
seizures)
6 to 48 hours
Alcoholic hallucinosis 
Alcoholic hallucinosis refers to 
hallucinations that develop within 
12 to 24 hours of abstinence and 
resolve within 24 to 48 hours (which 
is the earliest point at which delirium 
tremens typically develops)
 
Hallucinations are usually visual, 
although auditory and tactile 
phenomena may also occur. 
In contrast to delirium tremens, 
alcoholic hallucinosis is not 
associated with global clouding 
of the sensorium, but with specific 
hallucinations.
12 to 48 hours
Delirium Tremens (DT), seen in 
approximately 5% of those in 
alcohol withdrawal. Has a mortality 
rate of 5%. Death is usually due to 
arrhythmias or complicating illnesses 
such as pneumonia.
DTs generally produce hallucinations, 
disorientation, tachycardia, 
hypertension, low-grade fever, 
agitation, and diaphoresis. 
Withdrawal may also have an 
important impact on fluid and 
electrolyte status. Almost all patients 
in acute withdrawal are dehydrated 
as a result of diaphoresis, 
hyperthermia, vomiting, and 
tachypnea. Hypokalemia is common 
due to renal and extra-renal losses, 
alterations in aldosterone levels, and 
changes in potassium distribution 
across the cell membrane. 
Hypomagnesemia occurs frequently 
with DTs and may predispose 
to withdrawal seizures.  (7) 
Hypophosphatemia may occur due 
to malnutrition, may be symptomatic, 
and if severe, may contribute to 
cardiac failure and rhabdomyolysis.
48 to 96 hours
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tations. Listed below are some of the 
useful criteria to determine intensive 
care unit referral. (8)
• Age greater than 40 with concomi-
tant medical illness e.g. cardiac dis-
ease with failure, ischemia or angina, 
recent infarction 
• Severe electrolyte imbalances espe-
cially with ECG changes, severe acid 
base disturbances
• Hemodynamic instability
• Respiratory insufficiency, hypoxemia 
and or hypercapnia
• Potentially serious infections, includ-
ing sepsis
• GI pathology including pancreatitis, 
GI bleeding, fulminant hepatic failure, 
peritonitis




• Prior history of severe Delirium Tre-
mens
• Need for IV benzodiazepines or other 




These act on the gamma amino butyric 
acid (GABA) class of receptors. As a 
class effect they promote the binding 
of the major inhibitory neurotransmit-
ter GABA to the GABA A  sub type of 
the GABA receptors enhancing the 
frequency of GABA chloride channel 
openings. 
From a pharmacokinetic perspective 
most benzodiazepines have active 
metabolites and hence the duration 
of action seems to exceed the plasma 
half life. 
Figure 1 below demonstrates the meta-
bolic relationships between the various 
benzodiazepines. The approximate half 
life of the compounds is in parenthesis. 
S = short acting with half life < 6 hrs, 
I = intermediate with half lives 6 – 24 
hrs, and L = long acting with half life 
> 24 hrs.
In general, the longer acting agents with 
active metabolites are preferred since 
they are associated with a smoother 
course and less chance of recurrent 
withdrawal. (9) Conversely, Lorazepam, 
Oxazepam or Temazepam might be 
used in patients with advanced liver 
disease since they do not have active 
metabolites and with shorter half lives 
are less likely to cause over sedation.
The oral route is preferred if the patient 
can take medication orally. If the patient 
is too agitated or disoriented, IV route 
can be used. We do not advocate 
the use of IM administration since the 
absorption of the drug can be erratic 
and unpredictable. If IV access is tem-
porarily unavailable, IM Lorazepam can 
be used. (10) Table 2 gives approxi-
mate dosage equivalence with plasma 
half lives.
Dose titration
As a general guideline, younger patients 
with paucity of co morbid factors can be 
kept lightly sedated. Older patients with 
several cardio pulmonary co morbid 
risks factors usually need more seda-
tion and monitoring in the intensive 
care unit. The contention is that this 
sub group is at more risk and may not 
tolerate the systemic stress of major 
withdrawal.
The decision to put the patient on fixed 
drug therapy versus symptom triggered 
therapy should be made depending 
upon the severity of the withdrawal 
and prior history of delirium tremens 
and/or seizures. Symptom triggered 
therapy involves treatment only when 
the patient manifests symptoms. This is 
Figure 1. Metabolic degradation and plasma half lives of selected benzodiaz-
epines.











a reasonable strategy for the younger, 
less complicated patient. The use of 
symptom triggered therapy in selected 
patients was associated with similar 
outcomes when compared to fixed drug 
schedules. However, the symptom trig-
gered group received less amounts of 
Benzodiazepines and the duration of 
treatment was shorter. (12) Our person-
al experiences and practices involve 
using the symptom triggered approach 
for the younger patient with fewer co 
morbid conditions in mild to moderate 
withdrawal. The fixed dosing schedule 
is used in severe alcohol withdrawal 
with additional allowance for symptom 
triggered medications added on to the 
regimen.
Use of the CIWA –Ar scale
 The CIWA- Ar scale (The Clinical Insti-
tute Withdrawal Assessment for alco-
hol scale) is used widely as a means 
to gauge the severity of alcohol with-
drawal. (13) Though this scale is use-
ful, routine use of the scale alone is 
not sufficient to assess the severity of 
alcohol ?dependency/withdrawal. Most 
patients in acute alcohol withdrawal 
have multiple other co morbid condi-
tions. CIWA-Ar alone fails to take into 
consideration delirium from potential 
etiologies other than alcohol withdrawal 
syndrome. (14) Thus, an exhaustive his-
tory, physical and diagnostic evaluation 
is a necessary adjunct to the use of the 
CIWA-Ar scale. 
The CIWA –Ar is a numeric scale with 
numbers being assigned to severity 
of symptoms such as anxiety, nausea, 
headache and several other param-
eters. This brings in an element of sub-
jectivity. For example a nurse might 
score 4 on a patient’s tremor while 
another nurse might ascribe a score of 
6 to the same tremor. This inter observer 
variability can be mitigated to an extent 
by both nurses obtaining the CIWA –Ar 
score together at shift changes in the 
hospital. 
The practice of having pathways in insti-
tutions where a fixed dose of a benzodi-
azepine is attached to a number on the 
CIWA scale is fraught with inadequa-
cies. A CIWA –Ar score in such a prac-
tice might merit a dose of benzodiaz-
epine without taking into account age, 
liver function, previous withdrawal and 
or seizures and body weight. Thus, the 
patient could get too little or too much 
depending on the clinical situation. The 
most practical and pragmatic approach 
involves using the CIWA –Ar as a guid-
ing tool and then the individual physi-
cian should decide upon the agent, its 
dose, frequency and route based on 
clinical decision making. 
Severe refractory alcohol 
withdrawal
Severe refractory alcohol withdrawal/
delirium tremens can be seen occa-
sionally. Patients continue to withdraw 
despite treatment with very high doses 
of benzodiazepines. These patients 
might have low endogenous levels of 
GABA or conformational changes in the 
GABA receptor preventing effective sig-
naling and thus diminished efficacy of 
benzodiazepines. (15) In such patients, 
barbiturates, more specifically pheno-
barbital, can be very effective when 
given in addition to benzodiazepines. 
The combined effect of benzodiaze-
pines, which increase the frequency of 
GABA chloride channel opening, and 
barbiturates, which increase the dura-
tion of channel opening might enhance 
therapeutic responsiveness. Another 
reasonable alternative is propofol, 
which acts to open chloride channels 
in the absence of GABA, and may also 
antagonize the excitatory amino acids 
that are up regulated during alcohol 
withdrawal. (16,17) The use of Pheno-
barbital and propofol usually needs 
an intensive care unit environment and 
very often mechanical ventilation. 
Other pharmacologic 
agents
Ethanol: alcohol should not be used as 
a treatment in acute withdrawal. There 
are other agents and alternatives that 
appear to be safer and more effica-
cious. (18)
Baclofen: baclofen is a selective ago-
nist of the GABA - B receptor. (19) It is 
thought to exert its anti-spastic effect 
through this mechanism. The use of 
baclofen in acute alcohol withdrawal 
has been studied. (20) It appears to be 
equally efficacious as benzodiazepines 
and no significant differences were 
found between the groups receiving 
benzodiazepines and baclofen. How-
ever, baclofen is known to lower the 
seizure threshold and more information 
is needed prior to its routine use in alco-
hol withdrawal. 
Antipsychotics — Phenothiazines 
and butyrophenones lower the seizure 
threshold. They should be used with 
extreme caution in the withdrawing 
alcoholic. These agents may also inter-
fere with heat dissipation and, perhaps 
most importantly, do not exhibit cross-
tolerance with alcohol thus their efficacy 
is suspect. 
Antiepileptics: There is some interest 
in the use of anti-epileptics for the treat-
ment of acute alcohol withdrawal. In 
initial studies carbamazepine, an anti-
convulsant agent widely used in Europe 
for alcohol withdrawal syndrome, was 
shown to decrease the severity of with-
drawal symptoms comparable to the 
benzodiazepines in terms of adverse 
events, and was equally as effective as 
lorazepam in decreasing the symptoms 
of alcohol withdrawal. (21-23) How-
ever, a subsequent systemic review of 
a heterogeneous group of trials was 
unable to draw definite conclusions 
based on the variable study designs 
employed and the low overall mortality 
rates observed. (24) Hence, there is 
not a large enough body of evidence to 
suggest using carbamazepine in acute 
alcohol withdrawal. 
Chlormethiazole: It is a drug which is 
structurally related to thiamine (vitamin 
B1) but acts like a sedative, hypnotic, 
muscle relaxant and anticonvulsant. 
Chlormethiazole is a positive modu-
lator of γ-aminobutyric acid (GABA) 
[A] receptors. (25) Its use in the treat-
ment of alcohol withdrawal is not well 
established. It is widely used in alcohol 
withdrawal in Europe. Certain Euro-
pean studies allude to its efficacy in the 
treatment of alcohol withdrawal. (26-
28)  Intravenous infusions of this agent 
may cause cardiac arrhythmias and 
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hepatotoxicity with this agent has been 
reported. (29) It does not appear to be 
superior to benzodiazepines in alcohol 
withdrawal and more data is needed to 
recommend its use. 
Other agents with purported efficacy 
in alcohol withdrawal include gamma 
hydroxyl butyrate, (30) sodium valpro-
ate, (31) gabapentin. (32,33) However, 
the use of these agents remains off 
label. Large double blinded trials are 
required before recommending their 
routine use for alcohol withdrawal. 
Drug interactions from 
alcohol use
The interaction of alcohol with the 
CYP-450 enzyme system can be com-
plex and depends upon the duration 
of alcohol consumption. (34) Short-
term consumption leads to a competi-
tive inhibition of the CYP2E1 enzyme, 
whereas chronic use leads to its induc-
tion. CYP2E1 induction leads to an 
increased clearance of drugs such as 
warfarin, diazepam, rifamycin, mep-
robamate, pentobarbital, proprano-
lol, and alcohol itself, with the effect 
upon liver metabolism lasting for days 
to weeks after the discontinuation of 
alcohol. More importantly, the CYP2E1 
enzyme system converts otherwise safe 
substances into highly toxic metabo-
lites. These include industrial solvents, 
cocaine, some anesthetic agents (e.g., 
enflurane, methoxyflurane), isoniazid, 
phenylbutazone, and acetaminophen. 
Through the induction of this alternate 
pathway of drug metabolism, ordinarily 
innocuous doses of these agents may 
become hepatotoxic.
Conclusions
Alcohol withdrawal remains a leviathan 
cause of healthcare expenditure. A thor-
ough history and physical examination 
should precede the diagnosis of alco-
hol withdrawal. Other causes of delir-
ium should be ruled out and patient’s 
co morbid medical illnesses must be 
treated. Benzodiazepine class drugs 
remain the agents of choice. Longer 
acting agents are preferred because 
many have active metabolites that pre-
vent rapid loss of action. If possible oral 
medications should be tried. Symptom 
triggered approach is as effective as 
standing dose regimens. 
Delirium tremens should be treated early 
and aggressively with close monitoring 
of electrolytes and vital signs. Often the 
intravenous route is used for administra-
tion of drugs since there is clouding of 
the sensorium. Refractory delirium tre-
mens usually responds to barbiturates 
and propofol administered in an inten-
sive care unit setting and may require 
mechanical ventilation. Severe delirium 
tremens usually requires massive doses 
of benzodiazepines. The CIWA–Ar scale 
is a useful tool to gauge the severity 
of withdrawal. However, the physician 
should take into account patient factors 
prior to prescribing benzodiazepines 
based on the CIWA score.
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